By Soumya Ranjan From robust earnings at Schaeffler India and fresh investment headroom for PowerGrid to regulatory relief for Dr. Reddy’s and key updates from Hindalco, here are the stocks to watch for Wednesday’s trading session.
Indian Railway Finance Corporation
Following the government’s announcement that it would sell a 2% stake in IRFC through an offer for sale with a 2% green shoe option, the company will be under scrutiny. Opening for non-retail investors on February 25 and for retail investors on February 26, the OFS floor price is fixed at ₹104 per share. Stake sale proceeds could reach 4% if fully exercised.
Schaeffler India Ltd
While revenue increased 27.5% to ₹2,724 crore, the company’s Q4 net profit increased 35.9% year over year to ₹322.3 crore. EBITDA rose 30.8% to ₹484.5 crore, while margins improved from 17.3% to 17.8% over the previous year. For the year ending December 31, 2025, the board has suggested a dividend of ₹35 per equity share (face value ₹2), which, if accepted by shareholders, will be paid out within 30 days after the AGM.
PowerGrid
Power Grid Corporation of India has been granted more authority by the Cabinet Committee on Economic Affairs, increasing the amount of equity it can invest in each subsidiary from ₹5,000 crore to ₹7,500 crore, while maintaining the 15% net worth cap. The action will boost competitiveness in tariff-based bidding for vital infrastructure, allow POWERGRID to spend more in transmission projects, such as UHVAC and HVDC networks, and encourage the evacuation of renewable energy toward the 500 GW non-fossil target.
Hindalco Industries Ltd
According to the firm, AV Minerals (Netherlands) N.V. and its wholly owned subsidiary Novelis Inc. have signed a subscription agreement for the issuance of 13,33,333 common shares at a price of $150 each, totaling about $200 million. AV Minerals is a fully owned subsidiary of Hindalco and the only shareholder in Novelis.
Dr. Reddy’s Laboratories Ltd
The US Securities and Exchange Commission (SEC) has ended its investigation into potential unlawful payments and does not now plan to recommend enforcement action, according to a communication received by the pharmaceutical giant.
Lupin Ltd
The company’s ANDA for Brivaracetam Oral Solution 10 mg/mL, which is recommended for the treatment of partial-onset seizures in patients one month of age and older, has been approved by the USFDA. The medication is bioequivalent to UCB’s Briviact Oral Solution, and Lupin has started introducing it in the US. The IQVIA MAT December 2025 statistics showed that the reference drug’s expected yearly sales in the United States were $135 million.
Read:Stocks to Watch for February 25: Tata Group, Hexaware,RVNL, Waaree Energies and more
Disclaimer: This narrative is solely intended for educational reasons. The opinions and suggestions expressed above are not those of the Times of Dalal Street, but rather those of specific analysts or broking firms. Before making any financial decisions, we suggest investors to consult with qualified specialists.
Follow our WhatsApp channel: Join Now
Follow us on X: Follow us